Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTLA NYSE:NVS NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$12.60$13.53$6.83▼$28.25$1.76B1.939.58 million shs3.19 million shsNVSNovartis$152.14+0.1%$150.02$111.06▼$170.46$290.31B0.461.35 million shs1.41 million shsVYGRVoyager Therapeutics$3.80$3.95$2.64▼$5.55$229.60M1.26560,795 shs571,582 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics0.00%-7.83%-7.56%-4.26%+37.55%NVSNovartis0.00%+2.80%+4.67%-7.57%+34.92%VYGRVoyager Therapeutics0.00%+0.80%+0.26%+6.15%+30.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$12.60$13.53$6.83▼$28.25$1.76B1.939.58 million shs3.19 million shsNVSNovartis$152.14+0.1%$150.02$111.06▼$170.46$290.31B0.461.35 million shs1.41 million shsVYGRVoyager Therapeutics$3.80$3.95$2.64▼$5.55$229.60M1.26560,795 shs571,582 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics0.00%-7.83%-7.56%-4.26%+37.55%NVSNovartis0.00%+2.80%+4.67%-7.57%+34.92%VYGRVoyager Therapeutics0.00%+0.80%+0.26%+6.15%+30.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTLAIntellia Therapeutics 2.35Hold$20.2560.71% UpsideNVSNovartis 2.31Hold$141.20-7.19% DownsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50334.21% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, NVS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/12/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $49.005/12/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.004/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)4/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/28/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $58.004/28/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$28.00 ➝ $30.004/27/2026NTLAIntellia Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.004/27/2026NTLAIntellia Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$11.00 ➝ $15.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTLAIntellia Therapeutics$67.67M26.02N/AN/A$4.44 per share2.84NVSNovartis$54.53B5.32$10.75 per share14.15$20.40 per share7.46VYGRVoyager Therapeutics$40.37M5.69N/AN/A$2.87 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)NVSNovartis$13.98B$6.9821.8015.482.6724.87%38.82%15.16%7/21/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)Latest VYGR, NVS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion3/9/2026Q4 2025VYGRVoyager Therapeutics-$0.54-$0.46+$0.08-$0.46$10.49 million$13.46 million2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$3.082.02%+5.28%44.13%N/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTLAIntellia TherapeuticsN/A6.106.10NVSNovartis0.960.850.65VYGRVoyager TherapeuticsN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTLAIntellia Therapeutics88.77%NVSNovartis13.12%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipNTLAIntellia Therapeutics3.10%NVSNovartis0.01%VYGRVoyager Therapeutics12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTLAIntellia Therapeutics600139.72 million135.39 millionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableVYGR, NVS, and NTLA HeadlinesRecent News About These CompaniesWhat Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy ProgramsMay 20, 2026 | finance.yahoo.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026May 13, 2026 | markets.businessinsider.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026May 13, 2026 | globenewswire.comVoyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comVoyager Therapeutics (VYGR) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comVoyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026April 13, 2026 | seekingalpha.comAlfred Sandrock Sells 11,511 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockApril 4, 2026 | insidertrades.comVoyager Therapeutics (VYGR) price target increased by 12.22% to 17.17March 27, 2026 | msn.comVoyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum TranscriptMarch 23, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)March 19, 2026 | theglobeandmail.comGuggenheim Remains a Buy on Voyager Therapeutics (VYGR)March 13, 2026 | theglobeandmail.comDoes Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?March 12, 2026 | finance.yahoo.comVoyager Therapeutics: Q4 Earnings SnapshotMarch 10, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesMarch 9, 2026 | zacks.comVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, NVS, and NTLA Company DescriptionsIntellia Therapeutics NASDAQ:NTLA$12.60 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.52 -0.08 (-0.63%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$152.14 +0.13 (+0.09%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$152.00 -0.14 (-0.09%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Voyager Therapeutics NASDAQ:VYGR$3.80 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.78 -0.02 (-0.42%) As of 05/22/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
